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Amyotrophic lateral sclerosis is a fatal neurodegenerative disease 
of the upper and lower motor neuron of unknown etiology. Al-
though a familial cause for this disease has been suspected early 
one, it is only in the past two decades that advances in modern 
genetics led to the identification of more than 10 genes linked 
to familial ALS and helped us understand some of the complex 
genetic and environmental interactions that may contribute to 
sporadic ALS. In this article, we chronologically summarize the 
genetic breakthroughs in familial and sporadic ALS and depict 
how it shaped our understanding of disease pathogenesis and our 
quest for rational therapies.
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Introduction
Amyotrophic lateral sclerosis (ALS) is an adult on-
set, fatal neurodegenerative disorder, involving the large 
motor neurons of the brain and the spinal cord. It is char-
acterized clinically by progressive paralysis and eventual 
death from respiratory failure in three to five years.
ALS is mainly a sporadic disease of unknown etiol-
ogy. Although it has been first described by Charcot in 
1869, a lower motor neuron only form of the disease has 
been recognized almost two decades earlier by Aran and 
was called progressive muscular atrophy. Aran was also 
the first to put forward a familial etiology for this disease 
based on his description of a 45 years old sea captain with 
progressive muscular atrophy whose sister and two of his 
mother’s brothers died of similar symptoms (Aran, 1850). 
By 1880 Sir William Osler recognized that the Farr fami-
ly of Vermont had a dominantly inherited form of ALS. In 
1993, a century later, genetic analysis of ALS kindred in-
cluding the Farr family, led to the identification of SOD1 
as the first gene to cause familial ALS (1). Since then at 
least  10  additional  genes  have  been  linked  to  familial 
ALS/motor neuron disease. The discovery of these genes 
allowed the engineering of valuable animal models that 
were instrumental in our understanding of disease patho-
genesis and in testing different therapies. More recently, 
the tools of modern genetic were also applied to sporadic 
ALS in an attempt to decipher the complex genetic and 
environmental interactions that lead to ALS.
In this review we will highlight the lessons learned 
from genetic research in familial and sporadic ALS.
The genetics of familial ALS
Familial ALS represents about 10% of ALS cases. It 
can be inherited either as an autosomal dominant or re-
cessive trait. Adult onset autosomal dominant inheritance 
is more common than juvenile onset caused by recessive 
transmission. X-linked dominant inherited ALS has been 
reported in one family (2).
Mutations in SOD1 are the most common cause of 
familial ALS or ALS1, they are found in about 20% of 
ALS patients (1). To date more than 150 disease causing 
mutations have been reported, spread throughout all five 
exons of the gene. These mutations are mainly missense 
mutations but small deletions or insertions have also been 
described (www.alsod.org).
The mode of inheritance is autosomal dominant with 
age dependent penetrance except for the D90A that is re-
cessive in the Scandinavian population and dominant in 
others.
The phenotypes largely depend on the mutation with 
significant intra and inter familial variability. In the US 
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the A4V mutation is the most common and is character-
ized by a limb onset mainly lower motor neuron disease 
with rapid progression (3, 4). This contrast with the G37R 
or H46 R mutations that have slower disease progression 
of at least 10 years (3, 4).
Patients with SOD1 mutations are usually cognitively 
intact with rare exceptions (5). To explain the high preva-
lence of the A4V mutation in the United States, Saeed and 
colleagues determined that the North American A4V mu-
tation arose from two founders, Native American (82%) 
and European (18%), about 400-500 years ago at the time 
of Jamestown and Plymouth landing (6).
Pathologically,  SOD1-linked  familial  ALS  can  be 
distinguished from sporadic disease by the relative spar-
ing of the motor cortex, slight or mild corticospinal tract 
involvement that contrast with the severe atrophy of the 
anterior roots and the degeneration of lower motor neu-
rons. Engel and colleagues in 1959 reported a particular 
pattern of posterior column demyelination in the “mid-
dle root zone” in three patients with a familial syndrome 
that was clinically indistinguishable from ALS; one of 
the families reported had a rapid disease progression very 
suggestive of A4V mutation (7). This particular posterior 
column involvement has been since reported in autopsy 
tissue from patients with certain SOD1 mutations such 
as A4V, I113T or E100G mutations (8, 9). The surviv-
ing motor neurons also harbor SOD1 immunopositive in-
clusions that have not been detected in the other familial 
form of ALS or in sporadic disease (10).
The role of SOD1 mutations in familial ALS continue 
to be investigated. Significant insight into the pathogenesis 
of SOD1-linked familial ALS was gained from the study 
of the transgenic rodent models over expressing mutant 
SOD1 and in particular from the mouse model over ex-
pressing SOD1G93A mutation originally developed by Gur-
ney et al. in 1994 (11). Several studies have revealed that 
mutant SOD1 protein is misfolded and prone to aggre-
gate. These aggregates have been shown to recruit wild 
type protein (12), disrupt mitochondrial function (12) or 
axonal transport (13) and can induce ER stress (14). The 
beneficial effect of lowering SOD1 expression in the ani-
mal model is now being explored as a therapeutic option 
in human.
A little less than ten years after the discovery of SOD1 
mutations, ALSIN gene mutations were found to cause a 
rare, recessive, juvenile onset ALS or ALS2, ALSIN gene 
encodes a ubiquitously expressed protein named ALSIN. 
It localizes to the cytosolic face of endosomal membrane 
and acts as an exchange factor for Rab5 and other small 
GTPases and may be important for endosomal trafficking 
and axonal outgrowth (15). Few years’ later, an atypical 
form of ALS or ALS 8 in a Brazilian family was linked to 
a missense mutation in vesicle-associated membrane pro-
tein -associated protein B gene (VAPB) (16), emphasizing 
the role of vesicular transport in motor neuron survival. 
VAPB is also involved in the unfolded protein response 
and interacts with lipid binding proteins, linking lipid me-
tabolism dysfunction to the pathogenesis of ALS.
More recently the identification of TDP43 as the 
major disease protein in the ubiquinated inclusions in 
ALS and ALS /FTD led to the discovery of TDP43 mu-
tations in a subgroup of familial ALS patients or ALS10 
and in rare families with FTD or FTD/ALS (17). TDP43 
is a nuclear protein that is involved in many biological 
functions such as transcription and splicing regulation, 
mRNA stability (18) and micro RNA processing (19). 
In autopsy tissue as well as in animal or cell models, 
mutant protein form aggregates where TDP43 is phos-
phorylated, cleaved and translocated to the cytoplasm 
with  sometimes  loss  of  nuclear  staining.  FUS  gene 
encodes a DNA/RNA binding protein of similar func-
tion to TDP43. Mutations in FUS gene have emerged 
as the second most common cause of familial ALS or 
ALS6 (20, 21). Although phenotypically they are indis-
tinguishable from sporadic ALS, in our series, we found 
that when compared to SOD1 patients they have an ear-
lier age of onset, more frequent bulbar disease and a 
more rapid disease progression (22). Similar to TDP43, 
FUS  inclusions  were  found  to  co-localize  with  P62, 
ubiquitin and TDP43 in autopsy tissues of patients with 
sporadic ALS, TDP43 familial ALS, familial ALS with 
dementia and non-SOD1 familial ALS (10) suggesting 
that sporadic disease and non-SOD1 familial ALS share 
similar pathogenic mechanisms.
TDP43 and FUS are not the only motor neuron caus-
ing  genes  involved  in  DNA/RNA  metabolism,  ALS4 
linked gene, Senataxin (SETX), spinal musclar atrophy 
gene SMN and spinal muscular atrophy with respirato-
ry distress gene IGHMBP2 are also important for RNA 
processing. These findings have recently shifted the focus 
of research to the role of DNA and RNA in motor neuron 
degeneration and it can be expected that more DNA/RNA 
interacting proteins important for motor neuron viability 
will be discovered.
Finally the latest genetic research revealed two addi-
tional ALS associated genes: optineurin (OPTN) and val-
osin –containing Protein gene (VCP), both genes involved 
with Paget’s disease of bone. OPTN mutations also cause 
hereditary glaucoma and VCP causes inclusion body my-
opathy with frontotemporal dementia and Paget’s disease. 
The common glaucoma causing mutation in OPTN was 
shown to disrupt the ubiquitin-proteasome pathway and 
induces autophagy (23) whereas VCP is thought to be 
important for the coordination of protein degradation by 
both the ubiquitin-proteasome system and autophagy and 
mutations in VCP disrupt its function in protein degra-Familial amyotrophic lateral sclerosis, a historical perspective
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dation (24). These genes underscore the role of protein 
homeostasis and the interface between proteasomal sys-
tem and autophagy in the pathogenesis of ALS.
The Genetics of Sporadic ALS
The tremendous progress accomplished in modern 
genetics has allowed us to study the genetic susceptibility 
of complex diseases like sporadic ALS through genome 
wide  association  studies  (GWAS),  comparing  cases  to 
population based or family based controls.
Several GWAS and candidate genes association stud-
ies have been published in the past years with conflict-
ing results. It was soon discovered that the interpretation 
of GWAS results is challenging. The results depend on 
strong GWAS design that requires a large sample size and 
adequate population stratification. Most results published 
did not survive statistical correction for multiple testing 
and were not replicated in different population.
Recently several studies have established the 9p21 
locus as a susceptibility locus for ALS (25-27). In the 
study that used familial and sporadic cases the associa-
tion signal was mainly driven by the familial cases (27). 
This fact emphasizes the importance of case selection in 
GWAS design. Extra care should be taken in identifying 
and excluding familial cases.
Finally the paraoxonase (PON) gene cluster on chro-
mosome 7q21 has been extensively examined in the past 
years and has emerged as the most robust genetic risk 
factor for ALS. PON proteins play a role in preventing 
lipid oxidation and detoxifying organophosphates. Vari-
ants in PON genes were found to be associated with spo-
radic ALS in North American (28), Polish (29), Irish (30), 
French, French Canadian and Swedish populations (31).
Direct sequencing of the PON genes revealed at least 
seven mutations in familial and ALS patients that were 
predicted to alter PON function (32) implicating PON in 
sporadic and familial ALS.
Conclusion
The recent advances in the genetic of familial ALS 
made a significant contribution to our understanding of 
the pathogenesis of this fatal disease. The different genes 
discovered share similar biological functions that allowed 
us to identify common molecular pathway that lead to 
motor  neuron  degeneration.  These  pathways  are  also 
involved  in  other  hereditary  neurodegenerative  disease 
such as spinal muscular atrophy, spastic paraplegia and 
hereditary motor and sensory neuropathies. Developing 
specific therapies targeting these molecular mechanisms 
will not only be important for ALS but for a wide array of 
neurodegenerative diseases.
Despite all the progress achieved, the large majority 
of ALS genes remain unknown, and with the tools of mod-
ern genetics one can only expect that the number of genes 
involved with familial ALS will continue to increase.
The discovery of additional susceptibility genes that 
increase the risk for sporadic ALS, like the PON gene 
cluster, may help us better understand the complex en-
vironment interaction and may improve our modeling of 
sporadic disease.
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